Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Terence Hall"'
Publikováno v:
Translational Oncology, Vol 10, Iss 2, Pp 153-157 (2017)
ARQ 087 is a multi-tyrosine kinase inhibitor with potent activity against the FGFR receptor family, currently in Phase I clinical studies for the treatment of advanced solid tumors. The compound has a very safe profile and induces tumor regressions i
Externí odkaz:
https://doaj.org/article/7ae84e91e4cc4a6f904a17528c3b6814
Autor:
Yi Yu, Ronald E Savage, Sudharshan Eathiraj, Justin Meade, Michael J Wick, Terence Hall, Giovanni Abbadessa, Brian Schwartz
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140479 (2015)
As a critical component in the PI3K/AKT/mTOR pathway, AKT has become an attractive target for therapeutic intervention. ARQ 092 and a next generation AKT inhibitor, ARQ 751 are selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors that poten
Externí odkaz:
https://doaj.org/article/2c04147ffb5e4ca8bd0597d305175d7b
Publikováno v:
Molecular Cancer Therapeutics. 18:A034-A034
Background: AKT, a critical node in the PI3K/AKT/mTOR pathway, is one of the most frequently activated protein kinases in human cancers. ARQ 751 is a potent and highly selective pan-AKT inhibitor against AKT1, AKT2, and AKT3, and is currently in a ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b10813e62a4002c06d4b28d9d65807c6
https://doi.org/10.1158/1535-7163.targ-19-a034
https://doi.org/10.1158/1535-7163.targ-19-a034
Autor:
Terence Hall, Yunxia Wang, Bassel F. El-Rayes, Patricia LoRusso, Walid L. Shaib, Jasgit C. Sachdev, Ronald E. Savage, R. D. Harvey, Giovanni Abbadessa, Julia Kazakin, Drew W. Rasco, Amita Patnaik, Brian Schwartz, Kyriakos P. Papadopoulos, Anthony W. Tolcher
Publikováno v:
British Journal of Cancer
Background: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). Methods: Patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7ff18df66d5caa1b78e0dc94c879869
http://europepmc.org/articles/PMC5729432
http://europepmc.org/articles/PMC5729432
Autor:
Terence Hall, Brian Schwartz, Michael J. Wick, Sudharshan Eathiraj, Giovanni Abbadessa, Yi Yu
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with therapeutic interventions have been adv
The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with therapeutic interventions have been adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e80297afd8299ce4ed5e7719e7a826
https://doi.org/10.1097/cad.0000000000000486
https://doi.org/10.1097/cad.0000000000000486
Publikováno v:
Translational Oncology, Vol 10, Iss 2, Pp 153-157 (2017)
ARQ 087 is a multi-tyrosine kinase inhibitor with potent activity against the FGFR receptor family, currently in Phase I clinical studies for the treatment of advanced solid tumors. The compound has a very safe profile and induces tumor regressions i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccb675e1b71df59a50e4238caa9fd33
http://www.sciencedirect.com/science/article/pii/S1936523316302340
http://www.sciencedirect.com/science/article/pii/S1936523316302340
Autor:
Paula Olaizola, Massimo Roncalli, N. Navari, Karim Fiaccadori, Chiara Raggi, Fabio Marra, Giovanni Abbadessa, B. Piombanti, Gianfranco Alpini, Luca Di Tommaso, Terence Hall, Jesus M. Banales, Annarita Destro, Elisabetta Rovida, Margherita Correnti, Alessandra Elvevi, Pietro Invernizzi, Shannon Glaser, Michele Droz dit Busset, Vincenzo Mazzaferro, Fanyin Meng, Elisa Forti, Sherrie Bhoori, Alessio Gerussi, Mirella Pastore, Caterina Peraldo-Neia
Fibroblast growth factor receptor 2 (FGFR2) might have an important role in the pathogenesis and biology of cholangiocarcinoma (CCA). We examined FGFR expression in CCA tumor specimens obtained from patients and CCA cell lines, and then determined th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bab2b025cbe2443ffc855f41a68d0b3
http://hdl.handle.net/10281/240048
http://hdl.handle.net/10281/240048
Autor:
Nevena Damjanov, Sherrie Bhoori, Kyriakos P. Papadopoulos, Terence Hall, Michele Droz dit Busset, Fadi Braiteh, Christian Cotsoglou, Nicola Personeni, William P. Harris, Walid L. Shaib, Yunxia Wang, Brian Schwartz, Vincenzo Mazzaferro, Gianluca Masi, Vittorina Zagonel, Lorenza Rimassa, Julia Kazakin, Bassel F. El-Rayes, Filippo de Braud
Publikováno v:
British Journal of Cancer
Background Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa956fa25583c496cdf14ed67299e12
http://hdl.handle.net/11568/994323
http://hdl.handle.net/11568/994323
Autor:
Terence Hall, William P. Harris, Ronald E. Savage, Vincenzo Mazzaferro, Gianluca Masi, Christian Cotsoglou, Brian Schwartz, Nicola Personeni, Maria Lamar, Julia Kazakin, Walid L. Shaib, Lorenza Rimassa, Bassel F. El-Rayes, Sherrie Bhoori, Vittorina Zagonel, Yunxia Wang, Kyriakos P. Papadopoulos, Nevana Damjanov, Michele Droz-Dit-Busset
Publikováno v:
Cancer Research. 78:LB-232
Background: Fibroblast growth factors (FGFs) and their receptors (FGFRs) play important roles in cell proliferation, cell differentiation, cell migration, cell survival, protein synthesis, and angiogenesis. The FGFR family consist of four genes encod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::866d06a8deec5eda3a4742570916cd76
https://doi.org/10.1158/1538-7445.am2018-lb-232
https://doi.org/10.1158/1538-7445.am2018-lb-232
Autor:
Terence Hall, Yi Yu, Sudharshan Eathiraj, Pascal Schamber, Ron Savage, Gabi Schwartz, Brian Schwartz
Publikováno v:
Cancer Research. 78:4797-4797
The tropomycin kinase (Trk) receptor family contain Trk A, B and C that are encoded by the NTRK1, NTRK2, and NTRK3 genes respectively. Trk family kinases have been shown to play a very important role in the development and physiological functions of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20061c92d539e2790fa4e3554c8a4d38
https://doi.org/10.1158/1538-7445.am2018-4797
https://doi.org/10.1158/1538-7445.am2018-4797